Fluor lands $1.2bn contract for US pharmaceutical complex
Fluor has won a US$1.2bn (£970m) contract to design and build a pharmaceutical plant in North Carolina for the manufacture of diabetes medication.
Fluor’s full-scope contract follows on from the earlier provision of basic design services to client Novo Nordisk since the plans were announced in August 2015.
“Fluor is honored to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” said Juan Hernández, president of Fluor’s life sciences and advanced manufacturing business. “This project is the single largest life sciences facility investment in North Carolina’s history.”
“Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry and ability to deliver the full scope of work,” said Morten Nielsen, senior vice president, Novo Nordisk, and responsible for the construction of the new facility.
Nearly 2,500 craft employees and subcontractor jobs are expected at peak construction with about 700 new jobs at the facility when it is completed.
Construction is expected to be completed in mid-2019.